POLL>>🪙 | 💰 10 US Stocks Hit New Highs: LLY, JNJ, COST, KO, MO.....
November 13, 2026 screen: 13 U.S.-listed stocks with market caps of at least $10 billion were flagged for new all-time highs. The ten names below follow the supplied screen order. Price snapshots vary across sources, so the analysis uses the screen for selection and company disclosures for financial results.
-
Healthcare strength spans drugs and diagnostics: $Eli Lilly(LLY)$’s incretin franchise and DGX’s laboratory testing business both delivered double-digit revenue growth. JNJ also grew sales, but a proposed talc settlement and deal-related costs weighed on reported earnings.
-
Consumer staples show different growth drivers: COST’s October comparable sales rose 7.3% excluding gasoline and currency effects, while $Coca-Cola(KO)$ and $Coca-Cola Europacific(CCEP)$ both reported higher beverage volumes. MO’s smokeable products business relied on higher pricing as shipments declined.
-
Digital infrastructure reaches utilities and water treatment: $Evergy, Inc.(EVRG)$ signed a letter of intent with Digital Realty for a 1.4 GW project. $Veralto Corporation(VLTO)$ cited digital infrastructure investment among the factors supporting North American industrial demand for water treatment.
-
Hotel demand remains uneven across regions: $InterContinental Hotels Group PLC(IHG)$’s third-quarter revenue per available room rose 6.8% in the Americas and fell 3.3% in Greater China. The regional split makes local demand and pricing more informative than the global average alone.
1. $Eli Lilly(LLY)$ — Eli Lilly and Company
-
Core Business: Develops medicines for diabetes, obesity, oncology, immunology and neuroscience. Mounjaro and Zepbound anchor its incretin franchise.
-
Latest Developments: On October 29, 2026, Lilly raised the midpoint of full-year revenue guidance by $5.5 billion to a range of $91.0–$92.0 billion. The update also disclosed FDA approval of Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes. Eli Lilly and Company
-
Latest Earnings Highlights: Q3 2026. Revenue rose 39% YoY to $24.4 billion. Reported EPS rose 16% to $7.22 and adjusted EPS rose 7% to $7.48. Both included $4.57 per share of acquired in-process R&D charges.
-
Price Target Outlook: On November 9, 2026, Jefferies analyst Akash Tewari kept Buy and raised his target from $1,610 to $1,700.
2. $Johnson & Johnson(JNJ)$ — Johnson & Johnson
-
Core Business: Innovative Medicine develops treatments in areas including oncology and immunology. MedTech sells surgical, orthopedic, cardiovascular and vision products.
-
Latest Developments: On November 5, 2026, J&J announced FDA accelerated approval of Rybrevant Faspro for certain adults with recurrent or metastatic head and neck squamous cell carcinoma after prior treatment.
-
Latest Earnings Highlights: Q3 2026, reported October 13, 2026. Sales rose 5.9% YoY to $25.4 billion. GAAP diluted EPS fell to $0.09 from $2.12, reflecting a proposed talc settlement charge and deal-related costs. Adjusted EPS fell 7.5% to $2.59.
-
Price Target Outlook: On November 11, 2026, BofA Securities analyst Jason Gerberry reiterated Hold with a $275 target.
3. $Costco(COST)$ — Costco Wholesale Corporation
-
Core Business: Operates membership warehouses and e-commerce businesses in the U.S., Canada and other international markets. Its model combines merchandise sales with recurring membership fees.
-
Latest Developments: On November 4, 2026, Costco reported October net sales of $24.50 billion, up 12.6% YoY. Comparable sales rose 7.3% excluding gasoline prices and currency effects.
-
Latest Earnings Highlights: Fiscal Q4 2026, reported September 24, 2026. Net sales rose 11.2% YoY to $93.9 billion. Diluted EPS rose to $6.75 from $5.87, including a $0.15 net benefit from tariff refunds after partial reinvestment.
-
Price Target Outlook: On November 11, 2026, Mizuho Securities analyst David Bellinger maintained Buy and raised his target from $1,065 to $1,100.
4. $Coca-Cola(KO)$ — The Coca-Cola Company
-
Core Business: Owns beverage brands including Coca-Cola, Sprite and fairlife. It sells concentrates and syrups through its bottling system and also has finished-beverage operations.
-
Latest Developments: On October 27, 2026, Coca-Cola raised its full-year outlook after global unit case volume grew 5% in Q3. Organic revenue rose 7%.
-
Latest Earnings Highlights: Q3 2026. Net revenue rose 7% YoY to $13.4 billion. Operating margin rose to 33.4% from 32.0%, and comparable EPS increased 11% to $0.91.
-
Price Target Outlook: On October 28, 2026, UBS analyst Peter Grom maintained Buy and raised his target from $104 to $106.
5. $Altria(MO)$ — Altria Group, Inc.
-
Core Business: Sells smokeable and oral tobacco products primarily in the U.S. Its portfolio includes Marlboro cigarettes, Copenhagen smokeless tobacco and on! nicotine pouches.
-
Latest Developments: On October 28, 2026, Altria’s board authorized a $1 billion expansion of its existing share repurchase program. The expanded authorization expires December 31, 2027.
-
Latest Earnings Highlights: Q3 2026, reported October 29, 2026. Net revenue rose 1.0% YoY to $6.132 billion. Adjusted diluted EPS rose 4.8% to $1.52, and the smokeable products segment’s adjusted operating companies income margin was 64.5%.
-
Price Target Outlook: On October 30, 2026, UBS analyst Faham Baig kept Buy and raised his target from $79 to $83.
6. $Coca-Cola Europacific(CCEP)$ — Coca-Cola Europacific Partners plc
-
Core Business: Bottles and distributes beverages across Europe and its Australia, Pacific and Southeast Asia region. It serves retail and away-from-home channels.
-
Latest Developments: On November 3, 2026, CCEP reaffirmed full-year guidance and declared a €1.42 second-half interim dividend per share, payable December 3, 2026. That brought the full-year dividend to €2.24 per share.
-
Latest Earnings Highlights: Q3 2026 trading update. Revenue rose 6.5% YoY to €5.764 billion, or 5.8% on a comparable, currency-neutral basis. Unit case volume rose 3.6%; comparable, currency-neutral revenue per case rose 2.2%.
-
Price Target Outlook: On November 5, 2026, Barclays analyst Lauren Lieberman maintained a Buy-equivalent rating and raised her target from $112 to $124.
7. $Veralto Corporation(VLTO)$ — Veralto Corporation
-
Core Business: Water Quality sells analytical and treatment equipment to municipal and industrial customers. Product Quality & Innovation supplies marking, coding, packaging and color-management systems.
-
Latest Developments: On October 29, 2026, Veralto disclosed $1.1 billion deployed across four acquisitions year to date. The fourth, Cleanwater1, closed on October 5, 2026, for $465 million, subject to customary closing adjustments.
-
Latest Earnings Highlights: Q3 2026. Sales rose 7.5% YoY to $1.509 billion, with core sales up 5.1%. Adjusted operating margin expanded 170 basis points to 25.6%, and adjusted EPS rose 19.2% to $1.18.
-
Price Target Outlook: On November 2, 2026, Barclays analyst William Grippin maintained Overweight and raised his target from $117 to $129.
8. $Quest Diagnostics(DGX)$ — Quest Diagnostics Incorporated
-
Core Business: Provides clinical laboratory testing and diagnostic information to physicians, hospitals and consumers. Its network spans routine and specialty testing.
-
Latest Developments: On October 22, 2026, Quest raised its full-year revenue outlook to $12.065–$12.105 billion and adjusted diluted EPS guidance to $11.25–$11.35. Management cited strength across physician, hospital and consumer channels.
-
Latest Earnings Highlights: Q3 2026. Revenue rose 10.0% YoY to $3.10 billion. Operating income rose to $479 million from $386 million, and adjusted EPS rose 15.4% to $3.00 versus a published $2.85 consensus.
-
Price Target Outlook: On October 23, 2026, Morgan Stanley analyst Erin Wright reiterated a Buy-equivalent rating with a $260 target.
9. $InterContinental Hotels Group PLC(IHG)$ — InterContinental Hotels Group PLC
-
Core Business: Franchises and manages hotels worldwide. Brands span luxury and lifestyle, including Six Senses and InterContinental, through mainstream and extended-stay offerings such as Holiday Inn and Staybridge Suites.
-
Latest Developments: On October 22, 2026, IHG said it had completed $707 million of its $950 million 2026 buyback program. It remained on track to return more than $1.2 billion through buybacks and dividends in 2026.
-
Latest Earnings Highlights: Q3 2026 trading update. Global RevPAR rose 5.3% YoY, average daily rate increased 3.9%, and occupancy rose 0.9 percentage points. IHG opened 92 hotels and signed 164 in the quarter. The update disclosed operating metrics rather than quarterly EPS.
-
Price Target Outlook: On October 22, 2026, BofA Securities analyst Kate Xiao reiterated Buy and raised her target from $188 to $192.
10. $Evergy, Inc.(EVRG)$ — Evergy, Inc.
-
Core Business: Generates, transmits and distributes electricity through regulated utilities serving residential, commercial and industrial customers in Kansas and Missouri.
-
Latest Developments: On November 5, 2026, Evergy announced a letter of intent with Digital Realty for a 1.4 GW project. Three separately signed amendments to existing service agreements are expected to add approximately 250 MW of load.
-
Latest Earnings Highlights: Q3 2026. Adjusted EPS rose to $2.58 from $2.03 a year earlier, supported by warmer weather, recovery of regulated investments and higher revenue from large customers. Full-year adjusted EPS guidance rose from $4.14–$4.34 to $4.35–$4.50.
-
Price Target Outlook: On November 9, 2026, Mizuho Securities analyst Anthony Crowdell maintained Hold and raised his target from $85 to $91.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- MortimerDodd·11-18 11:23COST still stands out to me because the membership flywheel matters more than one month of comp sales, and KO plus JNJ are just classic cash flow grindersLikeReport
- PhoenixWhitman·11-18 11:23EVRG’s 1.4 GW data center load is the bigger rerate question, utility multiple really changes from here?LikeReport
